214
Figure 2
Related to the endothelial cell membrane there are four potential anti-angiogenic agents:
Those that inhibit the production of angiogenic factors (Bevasiranib, PF-04523655) or stimulate the production of antiangiogenic agents
(adPEDF.11, Lentivirus).
Those that neutralize the action of angiogenic agents in the extracellular environment (Ranibizumab, Bevacizumab, Pegaptanib, VEGF trap and
E10030).
Those that reduce the expression of membrane cellular receptors (AGN745 ) or interact with Integrins (Voloximab, JSM6427).
Those that interact in the inner space of the cell (Valatanib, TG100801/TG101095, Pazopanib, AGO13958, AL39324 Sirolimus, and Zybrestat).
